Tango Therapeutics, Inc. (TNGX)
NASDAQ: TNGX · IEX Real-Time Price · USD
7.59
+0.31 (4.26%)
May 2, 2024, 4:00 PM EDT - Market closed
Tango Therapeutics Revenue
In the year 2023, Tango Therapeutics had annual revenue of $36.53M with 46.93% growth. Revenue in the quarter ending December 31, 2023 was $5.43M, a -15.29% decrease year-over-year.
Revenue (ttm)
$36.53M
Revenue Growth
+46.93%
P/S Ratio
22.20
Revenue / Employee
$260,907
Employees
140
Market Cap
809.99M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 36.53M | 11.67M | 46.93% |
Dec 31, 2022 | 24.86M | -12.18M | -32.89% |
Dec 31, 2021 | 37.04M | 29.39M | 383.83% |
Dec 31, 2020 | 7.66M | -16.99M | -68.94% |
Dec 31, 2019 | 24.65M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Avanos Medical | 673.30M |
Artivion | 354.00M |
Definitive Healthcare | 251.42M |
National Research | 148.58M |
Sage Therapeutics | 91.06M |
Mobile-health Network Solutions | 7.87M |
Mesoblast | 7.25M |
Viridian Therapeutics | 314.00K |
TNGX News
- 4 weeks ago - Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights - Business Wire
- 2 months ago - Tango Therapeutics to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024 - GlobeNewsWire
- 3 months ago - Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference - GlobeNewsWire
- 4 months ago - Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study - PRNewsWire
- 6 months ago - Tango Therapeutics to Highlight Preclinical Data on PRMT5 Inhibitors at the Society for Neuro-Oncology (SNO) 28th Annual Meeting - GlobeNewsWire
- 6 months ago - Tango Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Highlights - GlobeNewsWire